ClinicalTrials.gg
Not yet recruitingNCT07855848AI-HBOT-DoCUpdated Oct 2, 2026

AI-Assisted Precision Hyperbaric Oxygen Therapy Based on Dynamic BIS-EEG Feedback for Patients With Disorders of Consciousness

An interventional study of AI-Assisted Personalized Hyperbaric Oxygen Therapy and Conventional Hyperbaric Oxygen Therapy in Disorders of Consciousness, Vegetative State and Minimally Conscious State, sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Consciousness Disorders with a site in China — 30 open to participants now, 31 under way, 1 of them phase 3. Consciousness Disorders · China.

Planned enrollment
2nd of 40
200 · median 60
Started
2026
with 7 others
No phase
36 of 70
18 open now
Primary completion
2027-06
later than 23 of 30 live
Registered
70th of 70
by date

Among the 70 studies in Consciousness Disorders with a site in China, this one is the 2nd largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 23 of the 30 other live ones, and was the 70th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

30 of the 70 studies in Consciousness Disorders with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Consciousness Disorders with a site in China, or all of them as a file.
02

Study summary

Disorders of consciousness (DoC) are severe neurological conditions characterized by impaired awareness and reduced interaction with the environment. Although hyperbaric oxygen therapy (HBOT) may promote neurological recovery, the optimal treatment strategy for individual patients remains unclear.

This study aims to develop and validate an artificial intelligence-assisted precision decision support system for HBOT based on dynamic BIS-EEG brain functional feedback. The system will integrate clinical information, neuroimaging data, physiological parameters, consciousness assessments, and HBOT treatment characteristics.

Continuous BIS-EEG monitoring will be performed during different phases of HBOT, including compression, oxygen exposure, air breaks, decompression, and post-treatment recovery. Artificial intelligence models will analyze these dynamic brain functional responses to predict treatment effectiveness and support personalized HBOT management.

The primary outcome will be improvement in consciousness assessed by the Coma Recovery Scale-Revised (CRS-R). Secondary outcomes include changes in consciousness state, cognitive and functional recovery, and treatment-related adverse events.

Read the detailed description

This prospective randomized controlled clinical study will evaluate whether an artificial intelligence-assisted precision hyperbaric oxygen therapy strategy improves clinical outcomes compared with conventional hyperbaric oxygen therapy in patients with disorders of consciousness.

Patients with disorders of consciousness, including vegetative state/unresponsive wakefulness syndrome and minimally conscious state, will receive standardized hyperbaric oxygen therapy. Multimodal clinical data will be collected, including demographic characteristics, disease etiology, disease duration, baseline consciousness assessment, neuroimaging findings, physiological parameters, BIS-EEG signals, and HBOT treatment parameters.

Dynamic BIS-EEG monitoring will be conducted throughout the entire HBOT session. Brain functional responses will be evaluated during the following phases: pre-treatment baseline, compression, hyperbaric oxygen exposure, air-break interval, repeated oxygen exposure, decompression, and post-treatment recovery.

The artificial intelligence system will integrate multimodal information using machine learning approaches to identify predictive biomarkers of neurological recovery and provide individualized decision support regarding HBOT treatment parameters, including treatment pressure, oxygen exposure duration, air-break strategy, treatment frequency, and treatment course.

The effectiveness of the AI-assisted decision support system will be evaluated by comparing predicted treatment responses with clinical outcomes. Clinical outcomes will include changes in Coma Recovery Scale-Revised (CRS-R) scores, consciousness state transitions, cognitive and functional recovery, and adverse events associated with HBOT.

This study is expected to provide an objective and personalized approach for optimizing HBOT management in patients with disorders of consciousness.

03

Conditions studied

  • Disorders of Consciousness
  • Vegetative State
  • Minimally Conscious State

Keywords

  • Hyperbaric Oxygen Therapy
  • BIS-EEG
  • Artificial Intelligence
  • Brain Functional Feedback
  • Precision Medicine
  • Clinical Decision Support System
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older.
  2. Diagnosis of disorders of consciousness, including vegetative state/unresponsive wakefulness syndrome (VS/UWS) or minimally conscious state (MCS).
  3. Disease duration of at least 28 days after the onset of brain injury.
  4. Stable medical condition suitable for hyperbaric oxygen therapy.
  5. Baseline consciousness assessment available using the Coma Recovery Scale-Revised (CRS-R).
  6. Ability to undergo standardized hyperbaric oxygen therapy sessions and complete clinical follow-up.
  7. Written obtained from the legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. to hyperbaric oxygen therapy, including untreated pneumothorax or other conditions considered unsafe for HBOT.
  2. Severe cardiovascular, respiratory, or systemic instability.
  3. Uncontrolled epilepsy or frequent seizures affecting assessment.
  4. Severe infection or metabolic disorders that may influence consciousness assessment.
  5. Previous participation in another interventional clinical trial that may affect neurological outcomes.
  6. Incomplete baseline clinical data or inability to complete follow-up assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AI-Assisted Personalized Hyperbaric Oxygen Therapy

    Participants will receive artificial intelligence-assisted precision hyperbaric oxygen therapy. The AI decision support system will integrate dynamic BIS-EEG brain functional feedback, clinical characteristics, neuroimaging findings, physiological parameters, and previous treatment responses to provide individualized recommendations for hyperbaric oxygen therapy parameters, including treatment pressure, oxygen exposure duration, air-break strategy, treatment frequency, and treatment course.

    Other: AI-Assisted Personalized Hyperbaric Oxygen Therapy

  • Active comparator
    Conventional Hyperbaric Oxygen Therapy

    Participants will receive conventional hyperbaric oxygen therapy according to standard clinical protocols determined by treating physicians. Treatment parameters will be selected based on routine clinical practice without artificial intelligence-assisted recommendations.

    Other: Conventional Hyperbaric Oxygen Therapy

Interventions

  • OtherAI-Assisted Personalized Hyperbaric Oxygen Therapy

    Participants will receive hyperbaric oxygen therapy optimized by an artificial intelligence-assisted clinical decision support system. The system integrates dynamic BIS-EEG brain functional feedback, clinical characteristics, neuroimaging findings, physiological parameters, and previous treatment responses to provide individualized recommendations for hyperbaric oxygen therapy parameters, including treatment pressure, oxygen exposure duration, air-break strategy, treatment frequency, and treatment course. Final treatment decisions will be made by qualified physicians.

  • OtherConventional Hyperbaric Oxygen Therapy

    Participants will receive conventional hyperbaric oxygen therapy according to standard clinical protocols determined by treating physicians. Treatment parameters will be selected based on routine clinical practice without artificial intelligence-assisted recommendations.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Coma Recovery Scale-Revised (CRS-R) Total Score at Week 12

    The Coma Recovery Scale-Revised (CRS-R) will be used to assess the level of consciousness. The CRS-R total score ranges from 0 to 23, with higher scores indicating better neurobehavioral function and a higher level of consciousness. The change in CRS-R total score from baseline to Week 12 will be calculated for each participant and compared between the AI-assisted precision hyperbaric oxygen therapy group and the conventional hyperbaric oxygen therapy group.

    Time frame: Baseline and 12 weeks after initiation of hyperbaric oxygen therapy

Secondary outcomes

  1. Change From Baseline in Glasgow Coma Scale (GCS) Total Score at Week 12

    The Glasgow Coma Scale (GCS) will be used to assess neurological responsiveness. The total score ranges from 3 to 15, with higher scores indicating better neurological responsiveness. Change from baseline to Week 12 will be compared between the AI-assisted precision hyperbaric oxygen therapy group and the conventional hyperbaric oxygen therapy group.

    Time frame: Baseline and 12 weeks after initiation of hyperbaric oxygen therapy

  2. Number of Participants With Hyperbaric Oxygen Therapy-Related Adverse Events

    The number and proportion of participants experiencing adverse events considered related to hyperbaric oxygen therapy will be recorded and compared between groups. Events of interest include middle-ear or sinus barotrauma, oxygen toxicity, seizures, pulmonary symptoms, hemodynamic instability, and other clinically significant treatment-related adverse events.

    Time frame: From the first hyperbaric oxygen therapy session through 7 days after the final treatment session

Other outcomes

  1. Discrimination Performance of the AI Model for Predicting Improvement in Consciousness State

    The predictive performance of the artificial intelligence model will be evaluated for predicting improvement to a higher consciousness state at Week 12. Discrimination will be assessed using the area under the receiver operating characteristic curve (AUROC). An AUROC of 0.5 indicates no discrimination, whereas values closer to 1.0 indicate better discrimination.

    Time frame: Prediction at baseline and during treatment for clinical outcome assessed at Week 12

07

Study locations

1 site
  • Shenzhen Baoxing Hospital
    Shenzhen, Guangdong 518020, China
    • Xiaofeng Chen Shenzhen Baoxing Hospital · Contactus@szus.org · 0755-28746265
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

Of 95 interventional studies with no phase under Consciousness Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 52. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855848
Lead sponsor
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Anmin Hu Shenzhen United Scheme Technology Co., Ltd.
Contact
anmin@szus.org
+86 17318061949
Xiaofeng Chen Shenzhen Baoxing Hospital
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion